Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Open Access
- 1 March 2021
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 36 (2), 362-370
- https://doi.org/10.3904/kjim.2019.198
Abstract
Background/Aims: The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Methods: Data from Korean patients in the Phase III, placebo-controlled, randomised DREAM (MEA112997/NCT01000506) and MENSA (MEA115588/NCT01691521) studies were included. Patients >= 12 years old with severe eosinophilic asthma received mepolizumab (DREAM: 75, 250 or 750 mg intravenously [IV]; MENSA: 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The primary outcome was the rate of clinically significant asthma exacerbations. Secondary outcomes included forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) and St George's Respiratory Questionnaire (SGRQ) scores (MENSA only). Blood eosinophil counts (BEC) and safety were assessed throughout. Results: Reductions in the rate of clinically significant asthma exacerbations were observed with the approved (100 mg SC) and bioequivalent (75 mg IV) doses of mepolizumab in Korean patients who participated in DREAM and MENSA. In MENSA, trends for improvements from baseline at week 32 in pre-bronchodilator FEV1 (75 mg IV group), ACQ-5 and SGRQ scores (in both treatment groups) were seen versus placebo in Korean patients. Incidence of on-treatment adverse events was similar in Korean patients versus non-Korean patients as were observed reductions from baseline in BEC. Conclusions: Mepolizumab treatment provided clinical benefits for Korean patients with severe eosinophilic asthma; the safety profile is consistent with the overall population.Keywords
Funding Information
- GlaxoSmithKline (DREAM, MEA112997/NCT01000506, MENSA, MEA115588/ NCT01691521)
- Korea Health Industry Development Institute (HI16C0992)
This publication has 19 references indexed in Scilit:
- Racial/ethnic differences in drug disposition and response: Review of recently approved drugsClinical Pharmacology & Therapeutics, 2015
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?The Journal of Clinical Pharmacology, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Severe asthma: future treatmentsClinical & Experimental Allergy, 2012
- Impact of Race on Asthma Treatment Failures in the Asthma Clinical Research NetworkAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Asthma: defining of the persistent adult phenotypesThe Lancet, 2006
- “Refractory” Eosinophilic Airway Inflammation in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Appropriate body-mass index for Asian populations and its implications for policy and intervention strategiesThe Lancet, 2004